Compare Sony Group Corp (SONY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sony Group Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Sony Group Corp trades at $23.52 (market cap $138.72B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Sony Group Corp and Vertex Pharmaceuticals Incorporated are close in size by market cap, and Sony Group Corp pays a 0.67% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| SONY | VRTX | |
|---|---|---|
Market Cap | $138.72B | $134.06B |
Sector | Technology | Health |
52-Week High | $30.26 | $557.96 |
52-Week Low | $19.32 | $376.62 |
Enterprise Value | $136.57B | $128.18B |
Dividend Yield | 0.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sony trades at $23.53, down 4.19% over 24 hours amid bearish technical signals. The company maintains strong operational cash flow of $2.32 trillion for 2025 and has beaten earnings expectations in two of the last three quarters. Analyst consensus remains bullish with 11 buy ratings versus 5 holds, though recent news highlights Sony's legal actions against Anthropic for copyright infringement and strategic focus on organic expansion over large-scale acquisitions.
The outlook is mixed: solid fundamentals and analyst support suggest long-term value, but near-term technical weakness and a projected net income decline to -$221.6 billion for 2026 pose risks. Investment opportunity lies in Sony's diversified entertainment ecosystem and content moat, while key risks include execution on profitability targets and competitive pressures in streaming and gaming.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
